ABMD

Politan Releases Investor Presentation Detailing Why New Directors Are Needed on the Masimo Board and Responds to Company’s Disingenuous Claims

Retrieved on: 
Tuesday, May 30, 2023
Other Professional Services, Professional Services, Finance, NO, Acquisition, Court, OR, WST, DXCM, Security (finance), ARE, INC, Common, Common stock, BLUE, WALL, RMD, Proxy, Letter, HOLX, ABMD, Suggestion, NDA, Bloomberg, ANY, EW, DEI Holdings, Management, Auction, Masimo, Vinnie Politan

Politan is seeking refreshed corporate governance at Masimo befitting a public company, not corporate control – and any suggestion otherwise is completely baseless.

Key Points: 
  • Politan is seeking refreshed corporate governance at Masimo befitting a public company, not corporate control – and any suggestion otherwise is completely baseless.
  • The Company’s recent claims that Politan has been unwilling to “engage” or “cooperate” with the Board are simply not credible.
  • For example, following Politan’s introductory meeting with Masimo management, the Board refused to meet and immediately adopted entrenching bylaws.
  • The participants in the proxy solicitation are Politan, Politan Capital Management GP LLC, Politan Capital Partners GP LLC, Politan Capital NY LLC, Politan Intermediate Ltd., Politan Capital Partners Master Fund LP (“Politan Master Fund”), Politan Capital Partners LP (“Politan LP”), Politan Capital Offshore Partners LP (“Politan Offshore” and collectively with Politan Master Fund and Politan LP, the “Politan Funds”), Quentin Koffey, Matthew Hall, Aaron Kapito and Michelle Brennan (collectively, the “Participants”).

FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial

Retrieved on: 
Wednesday, December 21, 2022
Medical Devices, Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Degenerative disease, MD, ECP, Multimedia, PCI, Patient, Ascension St. Mary's Hospital, Ascension Michigan, Physician, ABMD, FDA, EFS, Impella, Patient safety, Pharmaceutical industry, Medical device, Abiomed

Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial.

Key Points: 
  • Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial.
  • (Graphic: Business Wire)
    Impella ECP is the world’s smallest heart pump and the only heart pump compatible with small bore access and closure techniques.
  • Both patients enrolled in the trial received Impella ECP support during challenging left main coronary bifurcation stent procedures involving heavily calcified lesions.
  • The Impella ECP Pivotal Clinical Trial received FDA approval on March 2, 2022 and will enroll up to 217 patients in the U.S. Additional details about the pivotal trial are available here .

Johnson & Johnson Announces Extension of Abiomed Tender Offer to December 21, 2022

Retrieved on: 
Wednesday, December 14, 2022
General Health, Health, Medical Supplies, Other Health, Transfer, Heart, Corporation, Environment, Johnson & Johnson, Letter, Science, Annual report, Research, NYSE, ABMD, Behavior, Risk, Offer and acceptance, JNJ, Health, Acquisition, Security (finance), Cryptocurrency, Pharmaceutical industry, Schedule, Abiomed, Offer

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress.

Key Points: 
  • At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress.
  • On November 15, 2022, the Offeror filed with the SEC a tender offer statement on Schedule TO and Abiomed filed with the SEC a solicitation/recommendation statement on Schedule 14D-9 regarding the Offer.
  • Risk Factors, and in Johnson & Johnsons subsequent Quarterly Reports on Form 10-Q, and other filings by Johnson & Johnson with the SEC.
  • Copies of these filings are available online at www.sec.gov , at www.jnj.com or on request from Johnson & Johnson.

First Patients in the World Treated with Impella RP Flex with SmartAssist

Retrieved on: 
Monday, December 5, 2022
Cardiology, Surgery, Health, Medical Devices, Hospitals, Health Technology, Technology, Mobile, Wireless, Sodium bicarbonate, Food, Hackensack University Medical Center, Cardiac arrest, Patient, Pulmonary embolism, Survival rate, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ABMD, Weaning, Cardiogenic shock, Journal, Multimedia, PMA, The Journal of Heart and Lung Transplantation, HDE, Lung transplantation, Pharmaceutical industry, Medical device, MD, Impella, Heart

Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomeds newest heart pump for patients experiencing right heart failure.

Key Points: 
  • Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomeds newest heart pump for patients experiencing right heart failure.
  • Dr. Anderson and his colleague Yuriy Dudiy, MD, implanted Impella RP Flex on a 71-year-old patient who was having a minimally invasive valve surgery.
  • Dr. Andersons second Impella RP Flex case involved a 51-year-old patient who experienced cardiac arrest and received Impella support for four days after valve surgery.
  • Impella RP Flex is the latest iteration of the Impella RP heart pump.

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – SLDB, LFG, BNFT, ABMD

Retrieved on: 
Tuesday, November 15, 2022
United States Court of Appeals for the Ninth Circuit, ABIOMED, BP, Voya Financial, Telephone, Monteverde, Mergers and acquisitions, Lawyer, ABMD, Empire, Greenhouse effect (United States Supreme Court), Security (finance), Martindale-Hubbell, BNFT, Supreme court, Rising Star, Investment, Johnson & Johnson, Acquisition, LFG

Under the terms of the agreement, LFG shareholders are expected to receive $26.00 in cash per share they own.

Key Points: 
  • Under the terms of the agreement, LFG shareholders are expected to receive $26.00 in cash per share they own.
  • We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing.
  • We were listed in the Top 50 in the 2018-2021 ISS Securities Class Action Services Report.
  • Also, we have recovered or secured over a dozen cash common funds for shareholders in mergers & acquisitions class action cases.

ABIOMED INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abiomed, Inc. - ABMD

Retrieved on: 
Wednesday, November 16, 2022
KSF, Sale, JNJ, NYSE, ABMD, Johnson & Johnson, Abiomed

and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Abiomed, Inc. (NasdaqGS: ABMD) to Johnson & Johnson (NYSE: JNJ).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Abiomed, Inc. (NasdaqGS: ABMD) to Johnson & Johnson (NYSE: JNJ).
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • Please note that the merger is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Azenta Announces Nomination of Tina S. Nova, Ph.D. and Dorothy E. Puhy to Board of Directors

Retrieved on: 
Monday, November 14, 2022
Doctor of Philosophy, III, Board, SVP, Intention, University of California, Riverside, XGN, University of California, Irvine Medical Center, General manager, Leadership, University, Annual general meeting, Industry, ABMD, Sale, Company, Nasdaq, Reebok, EVP, Biology, Board of directors, Wendell Pritchett, Wharton School of the University of Pennsylvania, CEO, NASDAQ, Eaton Vance, Director, Arena Pharmaceuticals, Dana–Farber Cancer Institute, H5 (US company), Drug development, Management, Pharmaceutical industry, Sociology, Biochemistry, Pfizer, Novartis

"We are fortunate to have candidates of the caliber of Tina and Dorothy for Azenta's Board," said Steve Schwartz, President and CEO.

Key Points: 
  • "We are fortunate to have candidates of the caliber of Tina and Dorothy for Azenta's Board," said Steve Schwartz, President and CEO.
  • "They will bring tremendous life sciences experience to our Board and are proven value-creators in the space.
  • Their perspectives will be invaluable as Azenta continues to expand and evolve as a leading life sciences company."
  • Joseph R. Martin, Chairman of the Board of Directors, also commented, "We are pleased with our plans to welcome Tina and Dorothy as part of our ongoing Board refreshment as we continue to execute on our transformation strategy.

SHAREHOLDER ALERT: Weiss Law Reminds ABMD, BNFT, FRSH, and AIMC Shareholders About Its Ongoing Investigations

Retrieved on: 
Monday, November 7, 2022
Board, Voya Financial, CVR, AIMC, Director, Johnson & Johnson, Abiomed, Acquisition, View, FRSH, Multimedia, BNFT, Law, Curie–Weiss law, IPO, NASDAQ, ABMD, Audit

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Abiomed, Inc. (NASDAQ: ABMD), in connection with its proposed tender offer by Johnson & Johnson.

Key Points: 
  • Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Abiomed, Inc. (NASDAQ: ABMD), in connection with its proposed tender offer by Johnson & Johnson.
  • Under the tender offer, ABMD shareholders will receive $380.00 in cash, reflecting an enterprise value of approximately $16.6 billion, and a non-tradeable contingent value right (CVR) entitling the holder to receive up to $35.00 for each share of ABMD common stock owned.
  • Under the terms of the merger agreement, BNFT shareholders will receive $10.50 in cash for each share of BNFT common stock owned.
  • Under the merger agreement, AIMC shareholders will receive $62.00 in cash for each share of AIMC common stock owned.

ABIOMED INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abiomed, Inc. - ABMD

Retrieved on: 
Tuesday, November 1, 2022
Class Action Lawsuit, Professional Services, Legal, Company, ABMD, Sale, Time, LLC, NYSE, KSF, Nasdaq, JNJ, Johnson & Johnson, Abiomed

and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Abiomed, Inc. (NasdaqGS: ABMD) to Johnson & Johnson (NYSE: JNJ).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Abiomed, Inc. (NasdaqGS: ABMD) to Johnson & Johnson (NYSE: JNJ).
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • Please note that the merger is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

ABMD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ABIOMED, Inc. Is Fair to Shareholders

Retrieved on: 
Tuesday, November 1, 2022
Class Action Lawsuit, Professional Services, Legal, Thoma Bravo, ABMD, Advertising, Sale, Fraud, NASDAQ, Johnson & Johnson, ABIOMED, Security (finance)

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ABIOMED, Inc. (NASDAQ: ABMD) to Johnson & Johnson is fair to ABIOMED shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ABIOMED, Inc. (NASDAQ: ABMD) to Johnson & Johnson is fair to ABIOMED shareholders.
  • On behalf of ABIOMED shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
  • Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.